Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham Offspring Study

Clinical Chemistry

Volumn 42, Issue 4, 1996, Pages 515-523

  Contois, John H ^a,b,d   Mcnamara, Judith R ^a   Lammi Keefe, Carol J ^b   Wilson, Peter W F ^c   Massov, Tatyana ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c FRAMINGHAM HEART STUDY   (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

coronary heart disease; epidemiology; lipids; lipoproteins; standardization

Indexed keywords

APOLIPOPROTEIN B;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY RISK; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; STANDARDIZATION; TURBIDIMETRY;

EID: 0029971545     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.4.515     Document Type: Article

References (55)

1. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986;256:2835-8.
2. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987;257: 2176-80.
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous or graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA 1986;256:2823-8.
4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
5. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
6. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317: 1237-45.
7. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo study group of a randomized trial in healthy men. Lancet 1981:ii:1303-10.
8. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-7.
9. Manninen V, Elo O, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
10. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994; 344:1383-9.
11. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
12. The Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
13. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
14. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO Jr. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. Proc Natl Acad Sci U S A 1980;77:604-8.
15. Durrington PN, Hunt L, Ishola M, Kane J, Stephens WP. Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J 1986;56: 206-12.
16. Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins A-I, B as predictors of angiographically defined coronary heart disease. Arch Intern Med 1990;150:1629-33.
17. Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792-802.
18. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992;69:1251-4.
19. Coleman MP, Key TJ, Wang DY, Hermon C, Fentiman IS, Allen DS, et al. A prospective study of obesity, lipids, apolipoproteins and ischemic heart disease in women. Atherosclerosis 1992;92:177-85.
20. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Henneckens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
21. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994;24:444-53.
22. Marcovina SM, Albers JJ, Dati F, Ledue TB, Ritchie RF. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. Clin Chem 1991;37: 1676-82.
23. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem 1992;38:658-62.
24. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993;39:773-81.
25. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987;166:1-8.
26. Wilson PWF, Christianson JC, Anderson KM, Kannel WB. Impact of national guidelines for cholesterol risk factor screening: the Framingham Offspring Study. JAMA 1989;262:41-4.
27. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379-88.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
29. Brustolin D, Maierna M, Aguzzi F, Zoppi F, Tarenghi G, Berti G. Immunoturbidimetric method for routine determinations of apolipoproteins A-I and B. Clin Chem 1991;37:742-7.
30. Marcovina SM, Adolphson JL, Parlavecchia M, Albers JJ. Effects of lyophilization of serum on the measurement of apolipoproteins A-I and B. Clin Chem 1990;36:366-9.
31. Rifai N, Dufour DR, Cooper GR. Preanalytical variations in lipid, lipoprotein, and apolipoprotein testing. In: Rifai N, Warnick GR, eds. Laboratory measurement of lipids, lipoproteins, and apolipoproteins, 2nd ed. Washington, DC: AACC Press, 1994:43-64.
32. Stein EA. Clinical significance and measurement of apolipoproteins AI and B. In: Rifai N, Warnick GR, eds. Laboratory measurement of lipids, lipoproteins, and apolipoproteins, 2nd ed. Washington, DC: AACC Press, 1994:141-54.
33. Rosseneu M, Vercaemst R, Steinberg KK, Cooper GR. Some considerations of methodology and standardization of apolipoprotein B immunoassays [Review]. Clin Chem 1983;29:427-33.
34. Solakivi T, Salo MK, Puska P, Nikkari T. Plasma apolipoprotein B in middle-aged Finnish men: evidence for a regional gradient of apo B and lack of negative correlation between apo B and dietary linoleate in hyperapobetalipoproteinemia. Atherosclerosis 1988; 72:55-61.
35. Meilahn EN, Kuller LH, Stein EA, Caggiula AW, Matthews KA. Characteristics associated with apoprotein and lipoprotein lipid levels in middle-aged women. Arteriosclerosis 1988;8:515-20.
36. Alvarez C, Orejas A, Gonzalez S, Diaz R, Colomo LF. Reference intervals for serum lipids, lipoproteins, and apoproteins in the elderly. Clin Chem 1984;30:404-6.
37. Avogaro P, Cazzolato G, Bittolo Bon G, Belussi F, Quinci GB. Values of apo-AI and apo-B in humans according to age and sex. Clin Chim Acta 1979;95:311-5.
38. Kinlay S, Dobson AJ, Heller RF, Dickeson JE, Ryan S. Lipid and apolipoprotein levels in an Australian community. Med J Aust 1991;154:170-5.
39. Zunic G, Jelic-Ivanovic Z, Spasic S, Stojiljkovic A, Majkic-Singh N. Reference values for apolipoproteins A-I and B in healthy subjects, by age. Clin Chem 1992;38:566-9.
40. Waller KV, Ward KM, Rudmann SV. Serum lipids, lipoproteins, and apolipoproteins in the healthy elderly. Lab Med 1992;23:109-14.
41. Vermaak WJH, Kotze JP, van der Merwe AM, Becker PJ, Ubbink JB, Barnard HC, et al. Epidemiological reference ranges for low-density lipoprotein cholesterol and apolipoprotein B for identification of increased risk of ischaemic heart disease. S Afr Med J 1991;79:367-71.
42. Rifai N, King ME. Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. Clin Chem 1986;32:957-61.
43. Brunner D, Slutzky GM, Weisbort J, Schwartz S, Lingel R. Lipo-and apolipoproteins in a population survey subset in MONICA-Israel. Acta Med Scand 1988;(Suppl 728):159-64.
44. Alaupovic P, McConathy WJ, Fesmire J, Tavella M, Bard JM. Profiles of apolipoproteins and apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias [Review]. Clin Chem 1988;34(Suppl):B13-27.
45. Schaefer EJ, Lamon-Fava S, Conn SD, Schaefer MM, Ordovas JM, Castelli WP, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 1994;35: 779-92.
46. Campos H, McNamara JR, Wilson PWF, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1988;67:30-5.
47. Sniderman AD, Wolfson C, Teng B, Franklin FA, Bachorik PS, Kwiterovich PO Jr. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med 1982;97:833-9.
48. Grundy SM, Vega GL. Role of apolipoprotein levels in clinical practice [Review]. Arch Intern Med 1990;150:1579-82.
49. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-21.
50. Austin MA, Brunzell JD, Fitch WL, Krauss RM. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis 1990;10:520-30.
51. Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12:187-95.
52. Seishima M, Noma A, Torizawa H, Muto Y. Changes of serum apolipoprotein levels after oral administration of fat in human subjects. Atherosclerosis 1988;73:39-43.
53. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988;29:469-79.
54. McNamara JR, Cohn JS, Wilson PWF, Schaefer EJ. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem 1990; 36:36-42.
55. McNamara JR, Cole TG, Contois JH, Ferguson CA, Ordovas JM, Schaefer EJ. Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated. Clin Chem 1995;41:232-40.